Background: The androgen receptor gene is located on the X chromosome with a polymorphic tract of CAG repeats that is inversely correlated to the receptor’s transactivation activity. A short CAG tract is associated with hyperandrogenic disorders. In women, one of the X chromosomes is inactivated and the X chromosome inactivation (XCI) pattern varies among tissues. Previous studies of hyperandrogenic disorders only evaluated XCI in leukocytes. Objective: To evaluate whether the XCI pattern in leukocytes could be extrapolated to those in hair bulbs. Material: A total of 58 healthy women were used for this study. DNA was extracted from leukocytes (n = 58 women) and pubic (n = 53 women) and scalp hair (n = 21 women). Methods: Hpa II digested and undigested DNA samples underwent fluorescence PCR GeneScan® analysis. Results: A significant and positive correlation of XCI was found between leukocytes and hair bulbs. However, individual comparisons showed that 13 and 19% of the women presented a different leukocyte XCI pattern in pubic hair and scalp hair, respectively. Conclusion: The XCI pattern was similar in leukocytes and hair bulbs of normal women indicating that leukocyte DNA is useful for XCI analysis. However, the XCI pattern could vary among tissues from the same subject, indicating that care should be taken when extrapolating individual leukocyte XCI patterns to other tissue.

Keywords:
X chromosome inactivation, Healthy women, Peripheral leukocyte DNA, Hair bulb DNA, Androgen receptor gene
1.
Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001–3015.
2.
Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM: Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988;240:327–330.
3.
La Spada AR: Trinucleotide repeat instability: genetic features and molecular mechanisms. Brain Pathol 1997;7:943–963.
4.
Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW: Methylation of Hpa II and Hha I sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992;51:1229–1239.
5.
Rocha RO, Billerbeck AE, Pinto EM, Melo KF, Lin CJ, Longui CA, Mendonca BB, Bachega TA: The degree of external genitalia virilization in girls with 21-hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene. Clin Endocrinol 2008;68:226–232.
6.
Chamberlain NL, Driver ED, Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181–3186.
7.
Vottero A, Stratakis CA, Ghizzoni L, Longui CA, Karl M, Chrousos GP: Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. J Clin Endocrinol Metab 1999;84:1091–1095.
8.
Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320–3323.
9.
Ibáñez L, Ong KK, Mongan N, Jääskeläinen J, Marcos MV, Hugues IA, De Zegher F, Dunger DB: Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003;88:3333–3338.
10.
Santos ML, Sarkis AS, Nishimoto IN, Nagai MA: Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population. Cancer Detect Prev 2003;27:321–326.
11.
Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL: Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;82:3777–3782.
12.
Lappalainen S, Utriainen P, Kuulasmaa T, Voutilainen R, Jääskeläinen J: Androgen receptor gene CAG repeat polymorphism and X-chromosome inactivation in children with premature adrenarche. J Clin Endocrinol Metab 2008;93:1304–1309.
13.
Hickey TE, Legro RS, Norman RJ: Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:2789–2791.
14.
Shah NA, Antoine HJ, Pall M, Taylor KD, Azziz R, Goodarzi MO: Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:1939–1945.
15.
Legro RS, Shahbahrami B, Lobo RA, Kovacs BW: Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 1994;83:701–706.
16.
Lyon MF: X-chromosome inactivation and human genetic disease. Acta Paediatr Suppl 2002;91:107–112.
17.
Zeng SM, Yankowitz J: X-inactivation patterns in human embryonic and extra-embryonic tissues. Placenta 2003;24:270–275.
18.
Vogelstein B, Fearon ER, Hamilton SR, Preisinger AC, Willard HF, Michelson AM, Riggs AD, Orkin SH: Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res 1987;47:4806–4813.
19.
Calvo RM, Asunción M, Sancho J, San Millán JL, Escobar-Morreale HF: The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism. J Clin Endocrinol Metab 2000;85:1735–1740.
20.
Gale RE, Wheadon H, Boulos P, Linch DC: Tissue specificity of X-chromosome inactivation patterns. Blood 1994;83:2899–2905.
21.
Sharp A, Robinson D, Jacobs P: Age and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet 2000;107:343–349.
22.
Bittel DC, Theodoro MF, Kibiryeva N, Fischer W, Talebizadeh Z, Butler MG: Comparison of X chromosome inactivation patterns in multiple tissues from human females. J Med Genet 2008;45:309–313.
23.
Giwercman YL, Nordenskjold A, Ritzen EM, Nilsson KO, Ivarsson SA, Grandell U, Wedell A: An androgen receptor gene mutation (E653K) in a family with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency as well as in partial androgen insensitivity. J Clin Endocrinol Metab 2002;87:2623–2628.
24.
Hickey T, Chandy A, Norman RJ: The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161–165.
25.
Vottero A, Capelleti M, Giuliodori S, Viani I, Ziveri M, Neri TM. Bernasconi S, Ghizzoni L: Decreased androgen receptor gene methylation in premature pubarche: a novel pathogenetic mechanism? J Clin Endocrinol Metab 2006;91:968–972.
26.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
27.
Pegoraro E, Schimke RN, Arahata K, Hayashi Y, Stern H, Marks H, Glasberg MR, Carroll JE, Taber JW, Wessel HB, Bauserman SC, Marks WA, Toriello HV, Higgins JV, Appleton S, Schwartz L, Garcia CA, Hoffman EP: Detection of new paternal dystrophin gene mutations in isolated cases of dystrophinopathy in females. Am J Hum Genet 1994;54:989–1003.
28.
Busque L, Mio R, Mattioli J, Brais E, Blais N, Lalonde Y, Maragh M, Gilliland DG: Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 1996;88:59–65.
29.
El Kassar N, Hetet G, Brière J, Grandchamp B: X-chromosome inactivation in healthy females: incidence of excessive lyonization with age and comparison of assays involving DNA methylation and transcript polymorphisms. Clin Chem 1998;44:61–67.
30.
Bolduc V, Chagnon P, Provost S, Dubé MP, Belisle C, Gingras M, Mollica L, Busque L: No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans. J Clin Invest 2008;118:333–341.
31.
Amos-Landgraf JM, Cottle A, Plenge RM, Friez M, Schwartz CE, Longshore J, Willard HF: X chromosome-inactivation patterns of 1,005 phenotypically unaffected females. Am J Hum Genet 2006;79:493–499.
32.
Kristiansen M, Knudsen GP, Bathum L, Naumova AK, Sorensen TI, Brix TH, Svendsen AJ, Christensen K, Kyvik KO, Orstavik KH: Twin study of genetic and aging effects on X chromosome inactivation. Eur J Hum Genet 2005;13:599–606.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.